The effects of saffron supplementation on sepsis patients
- Conditions
- Sepsis patients.
- Registration Number
- IRCT20201129049534N8
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 90
Age between 18 and 80 years
Consent of the patient or his legal guardian
Digestive system with normal function and intestinal nutrition criteria
Diagnosis of sepsis based on sepsis-3 criteria and confirmation anesthesiologist or infectious disease specialist.
Patient or his legal guardian dissatisfaction
Patients who are hospitalized in the ICU for less than 48 hours or who cannot be fed enterally
Patients who do not have an indication for enteral nutrition on the first day, and based on the diagnosis of the special care department, it is confirmed and predicted that they will not be able to receive enteral nutrition in the future.
Patients who have cancer and are undergoing chemotherapy and taking cisplatin.
Patients with congenital and immune disorders, kidney and liver failure, and pancreatitis.
Patients taking anticonvulsants phenobarbital, Levetiracetam and phenytoin.
Patients undergoing dialysis.
Pregnancy and breastfeeding
Septic shock or severe sepsis
Patients expected to die within 2 days of admission to the ICU.
Patients with BMI<18.5 kg/m2
Patients using other herbal supplements
Allergy to herbal supplements or spices
Patients with GCS levels less than 3 or more than 13
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method